닥플 플러스
제15차 International Congress on Lipid & Atherosclerosis (ICoLA 2026) 2일차
한국지질ㆍ동맥경화학회
연수평점 :6점
오프라인
주관
한국지질ㆍ동맥경화학회
교육일자
2026-09-11
수강료
140,000원
교육형태
오프라인
등록일시
2026-07-27
교육시간
24시간 10분
연수평점
6점
장소
서울특별시 콘래드 서울 호텔(그랜드볼룸1~3, 파크볼룸3, 스튜디오2~3)
교육종류
내과
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-09-11 | 07:30~07:50 | Evolving LDL-C (Low-Density Lipoprotein Cholesterol) Management: Guidelines and the Role of Evolocumab | Sang Min Park(Eulji University, Republic of Korea) | - |
| 2026-09-11 | 07:50~08:10 | Is LDL-C Goal Attainment Enough? Pitavastatin/Fenofibrate in Mixed Dyslipidemia | Jae Hyun Bae(Seoul National University, Republic of Korea) | - |
| 2026-09-11 | 08:10~08:20 | Q&A | - | - |
| 2026-09-11 | 08:20~08:30 | Break | - | - |
| 2026-09-11 | 08:30~08:45 | (Oral presentation) Renal Lipidomic Profiling Reveals Boerhaavia diffusa Extract Ameliorates Saturated Fatty Acid Lipotoxicity and Mitochondrial Decay Independent of Systemic Adiposity | Lee On Ying(The Hong Kong Polytechnic University, China) | - |
| 2026-09-11 | 08:45~09:00 | (Oral presentation) Extrahepatic Bile Acid Synthesis Reprograms Multiorgan Cholesterol Flux in Cardiovascular Disease | Hosung Bae(University of Iowa, United States) | - |
| 2026-09-11 | 09:00~09:15 | (Oral presentation) Peroxiredoxin 3 (Prdx3) Deficiency Triggers cGAS (Cyclic GMP-AMP Synthase)–STING (Stimulator of Interferon Genes) Signaling Pathway-Induced Vascular Smooth Muscle Cell Senescence and Phenotypic Switching in Abdominal Aortic Aneurysm | Moajury-Jung(Ewha Womans University, Republic of Korea) | - |
| 2026-09-11 | 09:15~09:30 | (Oral presentation) Sphingosine-1-Phosphate Receptor 1 Deletion in Smooth Muscle Cells Protects Against Atherosclerosis in Apolipoprotein E (apoE)-Deficient Mice by Reducing Lipid Droplet Formation | Bernardo Trigatti(Hamilton Health Sciences, Canada) | - |
| 2026-09-11 | 09:10~09:25 | (Oral presentation) Senolytic Therapy Attenuates Atherosclerosis and Metabolic Dysfunction by Targeting Cellular Senescence in Western Diet-Fed Low-Density Lipoprotein Receptor (Ldlr) Knockout (KO) Mice | Hye Rang Park(KRIBB, Republic of Korea) | - |
| 2026-09-11 | 09:25~09:40 | (Oral presentation) The Role of Leucine-Rich Glioma-Inactivated 3 (LGI3) in Adipocytes and Macrophages in Atherosclerosis | Do Hee Yu(Ewha Womans University, Republic of Korea) | - |
| 2026-09-11 | 09:40~09:55 | (Oral presentation) Cyclic Induction of Oct4, Sox2, Klf4, and c-Myc (OSKM) Expression Mitigates Atherosclerosis through Vascular Anti-Inflammatory Remodeling Independent of Systemic Metabolic Effects | Young Hoon Seo(KRIBB, Republic of Korea) | - |
| 2026-09-11 | 09:55~10:00 | Q&A | - | - |
| 2026-09-11 | 10:00~10:10 | Break | - | - |
| 2026-09-11 | 10:10~10:20 | Opening Address | - | - |
| 2026-09-11 | 10:20~11:00 | Lipoprotein(a): The Next Frontier in Cardiovascular Prevention | Sotirios Tsimikas(University of California, San Diego, USA) | - |
| 2026-09-11 | 11:00~11:40 | 그림 속의 의학 | Sung Koo Han(Seoul National University, Republic of Korea) | - |
| 2026-09-11 | 11:40~12:45 | Lunch | - | - |
| 2026-09-11 | 12:45~13:15 | The Quiet Signal, No Longer — Triglyceride at the Crossroads of Insulin Resistance and Cardiometabolic Risk | Cheol-Young Park(Sungkyunkwan University, Republic of Korea) | - |
| 2026-09-11 | 13:15~13:20 | Q&A | - | - |
| 2026-09-11 | 13:20~13:40 | Reliability of lipid-related content on Korean health YouTube | Il Hak Lee(Yonsei University, Republic of Korea) | - |
| 2026-09-11 | 13:40~13:45 | Q&A | - | - |
| 2026-09-11 | 13:45~13:55 | Break | - | - |
| 2026-09-11 | 13:55~14:13 | Korean epidemiology and risk modifiers for establishing LDL-C goal strategies | Jong Han Choi(Konkuk University, Republic of Korea) | - |
| 2026-09-11 | 14:13~14:31 | Practical algorithm for intensive lipid lowering therapy in the 2026 Korean guidelines | Jae Hoon Chung(Gachon University, Republic of Korea) | - |
| 2026-09-11 | 14:31~14:49 | Nutritional management and lifestyle modification tailored to the Korean dietary pattern | Ga Ram Cho(Hannam University, Republic of Korea) | - |
| 2026-09-11 | 14:49~15:07 | Optimized lipid management for special populations | Byung Sik Kim(Hanyang University, Republic of Korea) | - |
| 2026-09-11 | 15:07~15:25 | Discussion | - | - |
| 2026-09-11 | 15:25~15:35 | Break | - | - |
| 2026-09-11 | 15:35~16:15 | Closing the Gap Between Guidelines and Reality in Dyslipidemia Management | Michal Vrablík(Charles University, Czech Republic) | - |
| 2026-09-11 | 16:15~16:25 | Break | - | - |
| 2026-09-11 | 16:25~16:45 | PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition in Primary Prevention: Insights from VESALIUS-CV (Vascular Events Study of PCSK9 Inhibition in High-Risk Patients Without Prior Ischemic Events–Cardiovascular) and Clinical Implications | Doo Sun Sim(Chonnam National University, Republic of Korea) | - |
| 2026-09-11 | 16:45~17:05 | Ultra-Low LDL-C and Brain Safety: Hemorrhagic Stroke and Cognition | Kwang-Yeol Park(Chung-Ang University, Republic of Korea) | - |
| 2026-09-11 | 17:05~17:25 | Early Combination Therapy in Primary Prevention | Ho Youn Won(Chung-Ang University, Republic of Korea) | - |
| 2026-09-11 | 17:25~17:55 | Discussion | - | - |
| 2026-09-11 | 07:30~07:50 | Bridging Guidelines and Practice: Strategic Implementation of Combination Therapy in Lipid Management | In-ki Moon(Soonchunhyang University, Republic of Korea) | - |
| 2026-09-11 | 07:50~08:00 | Q&A | - | - |
| 2026-09-11 | 08:00~08:30 | Break | - | - |
| 2026-09-11 | 08:30~08:50 | Bempedoic Acid: LDL-C Lowering Beyond Statins – Evidence and Clinical Role | Che Wan Lim(Catholic Kwandong University, Republic of Korea) | - |
| 2026-09-11 | 08:50~09:10 | Optimizing Non-Statin Therapy: PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors and inclisiran | Kyung Hee Kim(Incheon Sejong Hospital, Republic of Korea) | - |
| 2026-09-11 | 09:10~09:30 | Emerging Lp(a) (Lipoprotein(a))-Lowering Therapies: siRNA (small interfering RNA), ASO (Antisense Oligonucleotide), and Beyond | Yu Chen Wang (Asia University, Taiwan)(Asia University, Taiwan) | - |
| 2026-09-11 | 09:30~10:00 | Discussion | - | - |
| 2026-09-11 | 10:00~10:10 | Break | - | - |
| 2026-09-11 | 11:40~12:45 | Lunch | - | - |
| 2026-09-11 | 13:45~13:55 | Break | - | - |
| 2026-09-11 | 13:55~14:15 | Lipoprotein(a) in Korean patients: Real-world data, cardiovascular risk, and clinical implications | Sang Min Park(Eulji University, Republic of Korea) | - |
| 2026-09-11 | 14:15~14:35 | Lipoprotein(a) and Coronary Atherosclerosis in Vietnam: Real-World Data and Emerging Cardiovascular Risk | Hoang Anh Tien(Hue University, Vietnam) | - |
| 2026-09-11 | 14:35~14:55 | Measuring Lipoprotein(a) in clinical practice: Assay challenges, standardization, and interpretation | Sang Guk Lee(Yonsei University, Republic of Korea) | - |
| 2026-09-11 | 14:55~15:25 | Discussion | - | - |
| 2026-09-11 | 15:25~15:35 | Break | - | - |
| 2026-09-11 | 16:15~16:25 | Break | - | - |
| 2026-09-11 | 16:25~16:45 | CETP (Cholesteryl Ester Transfer Protein) Inhibition Revisited: Obicetrapib for LDL-C (Low-Density Lipoprotein Cholesterol) Reduction and ASCVD (Atherosclerotic Cardiovascular Disease) Risk Management | Mariko Harada-Shiba(Osaka Medical and Pharmaceutical University, Japan) | - |
| 2026-09-11 | 16:45~17:05 | APOC3 (Apolipoprotein C-III) Inhibition: Targeting Triglyceride-Rich Lipoproteins and Residual Risk | Jin Wi(Gachon University, Republic of Korea) | - |
| 2026-09-11 | 17:05~17:25 | ANGPTL3 (Angiopoietin-Like Protein 3) Inhibition: Expanding Therapeutic Opportunities Beyond LDL-C (Low-Density Lipoprotein Cholesterol) | Hye Moon Chung(Kyunghee University, Republic of Korea) | - |
| 2026-09-11 | 17:25~17:55 | Discussion | - | - |
| 2026-09-11 | 07:30~07:50 | Paving the Road for Optimal LDL-C Management: New Evidence on Intensive LDL-C Targeting from the Ez-PAVE Trial | Yong-Joon Lee(Yonsei University, Republic of Korea) | - |
| 2026-09-11 | 07:50~08:00 | Q&A | - | - |
| 2026-09-11 | 08:00~08:30 | Break | - | - |
| 2026-09-11 | 08:30~08:48 | Lipid-Lowering Therapy in People Living with Human Immunodeficiency Virus (HIV) | So Ree Kim(Korea University, Republic of Korea) | - |
| 2026-09-11 | 08:48~09:06 | Lipid-lowering therapy in Patients with Cancers | Hiroshi Akazawa(Kanazawa Medical University, Japan) | - |
| 2026-09-11 | 09:06~09:24 | Lipid-lowering Therapy in Patients with CKD (Chronic Kidney Disease) | Eun-sil Koh(The Catholic University of Korea, Republic of Korea) | - |
| 2026-09-11 | 09:24~09:42 | Cardiovascular Prevention in Hemodialysis: Is Omega-3 Back? | Sang Ho Jo(Hallym University, Republic of Korea) | - |
| 2026-09-11 | 09:42~10:00 | Discussion | - | - |
| 2026-09-11 | 10:00~10:10 | Break | - | - |
| 2026-09-11 | 11:40~12:45 | Lunch | - | - |
| 2026-09-11 | 13:45~13:55 | Break | - | - |
| 2026-09-11 | 13:55~14:15 | Evolution of Vulnerable Plaques: From Natural History to Preventive Intervention | Lee Jin Ho(Kyunghee University, Republic of Korea) | - |
| 2026-09-11 | 14:15~14:35 | High-Risk Plaque Features on CCTA (Coronary Computed Tomography Angiography): Identification and Clinical Implications | Sang Yoon Lee(Sungkyunkwan University, Republic of Korea) | - |
| 2026-09-11 | 14:35~14:55 | Coronary Physiology and Plaque Vulnerability: Linking Function to Risk | Seok Hun Yang(Seoul National University, Republic of Korea) | - |
| 2026-09-11 | 14:55~15:25 | Discussion | - | - |
| 2026-09-11 | 15:25~15:35 | Break | - | - |
| 2026-09-11 | 16:15~16:25 | Break | - | - |
| 2026-09-11 | 16:25~16:43 | Defining Residual Cardiovascular Risk in the Post-LDL Era: Unmet Needs and Mechanisms | Hyung-joon Joo(Korea University, Republic of Korea) | - |
| 2026-09-11 | 16:43~17:01 | Targeting Residual Risk: Lp(a), Triglyceride-Rich Lipoproteins, and Inflammation | Sung Gyun Ahn(Yonsei University, Republic of Korea) | - |
| 2026-09-11 | 17:01~17:19 | Residual Cardiovascular Risk Beyond LDL-C (Low-Density Lipoprotein Cholesterol): The Central Role of ApoB (Apolipoprotein B) Lipoproteins | John Chapman(Sorbonne University, France) | - |
| 2026-09-11 | 17:19~17:37 | Navigating Residual Thrombotic and Inflammatory Risk: Lessons from AF (Atrial Fibrillation) and Stable CAD (Coronary Artery Disease) Management | Satoshi Yasuda(Tohoku University, Japan) | - |
| 2026-09-11 | 17:37~17:55 | Discussion | - | - |
| 2026-09-11 | 07:30~07:45 | The Role of DPP-4 (Dipeptidyl Peptidase-4) Inhibitors in Korean Diabetes Care: Focusing on K-Evidence | Yun Kyung Cho(University of Ulsan, Republic of Korea) | - |
| 2026-09-11 | 07:45~08:00 | The Smaller The Better : Rovazet | Ji Hoon Kang(Seoul National University, Republic of Korea) | - |
| 2026-09-11 | 08:00~08:10 | Q&A | - | - |
| 2026-09-11 | 08:10~08:30 | Break | - | - |
| 2026-09-11 | 08:30~08:50 | Ion channels in Atherosclerosis: From Calcium Flux to Vascular Dysfunction | Sung Joon Kim(Seoul National University, Republic of Korea) | - |
| 2026-09-11 | 08:50~09:10 | Energy Metabolism and Lipid Oxidation in Cardiometabolic Pathophysiology | Jin Han(Inje University, Republic of Korea) | - |
| 2026-09-11 | 09:10~09:30 | Lipoprotein(a): Oxidized phospholipids, and Atherosclerosis | Jung-Woo Son(Yonsei University, Republic of Korea) | - |
| 2026-09-11 | 09:30~10:00 | Discussion | - | - |
| 2026-09-11 | 10:00~10:10 | Break | - | - |
| 2026-09-11 | 11:40~12:45 | Lunch | - | - |
| 2026-09-11 | 12:45~13:00 | Genetic and epigenetic mechanisms underlying sex differences in cardiometabolic disease | Soo Jin Kim(Kosin University, Republic of Korea) | - |
| 2026-09-11 | 13:00~13:15 | Early-Onset Dyslipidemia in Young Adults: Screening Strategies and Lifetime ASCVD (Atherosclerotic Cardiovascular Disease) Risk Assessment | Jae Hyun Bae(Hallym University, Republic of Korea) | - |
| 2026-09-11 | 13:15~13:30 | Menopause and Cardiometabolic Transition: Optimizing Lipid Management in Midlife Women | In Jeong Cho(Ewha Womans University, Republic of Korea) | - |
| 2026-09-11 | 13:30~13:45 | Discussion | - | - |
| 2026-09-11 | 13:45~13:55 | Break | - | - |
| 2026-09-11 | 13:55~14:15 | Fatty liver and residual cardiovascular risk: Epidemiology and clinical implications | Eun-Jung Rhee(Sungkyunkwan University, Republic of Korea) | - |
| 2026-09-11 | 14:15~14:35 | From Lipotoxicity to Atherosclerosis: MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)/MetALD (Metabolic Dysfunction-Associated Alcohol-Related Liver Disease) Subtypes and Cardiovascular Risk | Su Jong Yu(Seoul National University, Republic of Korea) | - |
| 2026-09-11 | 14:35~14:55 | Therapeutic Strategies for Cardiometabolic Risk Reduction in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) | Toru Miyoshi(Okayama University, Japan) | - |
| 2026-09-11 | 14:55~15:25 | Discussion | - | - |
| 2026-09-11 | 15:25~15:35 | Break | - | - |
| 2026-09-11 | 16:15~16:25 | Break | - | - |
| 2026-09-11 | 16:25~16:45 | Lipid Remodeling of Adipose Tissue: The Hidden Link Between Obesity and Atherosclerosis | Yun Hee Lee(Seoul National University, Republic of Korea) | - |
| 2026-09-11 | 16:45~17:05 | Remnant Cholesterol and Residual Cardiovascular Risk in Obesity | Young Sang Lyu(Chosun University, Republic of Korea) | - |
| 2026-09-11 | 17:05~17:25 | Dual Targeting of Lipid and Weight: Emerging Therapies and Clinical Strategies | Chang Hee Jung(University of Ulsan, Republic of Korea) | - |
| 2026-09-11 | 17:25~17:55 | Discussion | - | - |
비고
-교수, 봉직의, 개원의 : 조기 등록 80,000원/100,000원 / 사전 등록 100,000원/120,000원 / 현장 등록 120,000원/140,000원-전임의, 전공의, 군의관/공보의, 연구원, 간호사, 영양사, 약사, 기업회원, 기타 : 조기 등록 50,000원 / 사전 등록 60,000원 / 현장 등록 70,000
문의처
담당자
ICoLA2026 준비사무국
연락처
02-6098-7061
이메일
lipid@planbear.co.kr